Microbial therapeutics: New opportunities for drug delivery

With >40 clinical trials underway, we are nearing the first FDA-approved live microbial therapeutic. Here, Giovanni Traverso, MIT and Harvard Medical School Assistant Professor, and colleagues Miguel Jimenez and Institute Professor Robert Langer from MIT discuss the significant challenges of admi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jimenez, Miguel, Langer, Robert, Traverso, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2019
Materias:
News
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504217/
https://www.ncbi.nlm.nih.gov/pubmed/31028093
http://dx.doi.org/10.1084/jem.20190609
Descripción
Sumario:With >40 clinical trials underway, we are nearing the first FDA-approved live microbial therapeutic. Here, Giovanni Traverso, MIT and Harvard Medical School Assistant Professor, and colleagues Miguel Jimenez and Institute Professor Robert Langer from MIT discuss the significant challenges of administering live microorganisms to patients and the opportunities for drug delivery of these new complex therapeutics.

Ejemplares similares